Imagion Biosystems has announced the successful completion of the renounceable rights issue raising approximately $3.6 million.
Read Imagion Biosystems’ Right Issue raises $3.6 million.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal